Recent advances in bioisosteric modifications for targeting Alzheimer's disease pathways.

The drug development process is highly challenging due to high cost, ethical consideration and takes a long time to reach in to the market for the ultimate benefit of the patients. Considering the global health issues, brain disorders such as Parkins…

Preview only. Read the full abstract at the source